Finance

The company’s latest letter from the FDA wasn’t what investors had hoped for.

The market showed signs of weakness coming out of the holiday weekend.

The company’s shares got caught up in the uncertainty caused by a government crackdown on U.S.-listed Chinese companies.

Here are two potential reasons for the decline in the electric-car maker’s stock price today.

There’s a lot of collateral damage being caused by the downdraft.

A look at auto news.

This semiconductor chip designer is just scratching the surface of multibillion-dollar opportunities.

The CBD company’s shares bounced back after an early 10% drop today.

The company announced preliminary revenue per available room estimates for the second quarter of 2021, and a 1-for-10 reverse stock split.

Increasing its share count by 5% didn’t seem like such a big deal, but it’s off the table in a move to please its retail investors instead of its balance sheet.

Want to max out the size of your Social Security checks? You’re going to have to earn a lot of money.

New data from Israel appears to be weighing on both vaccine stocks.

Generally speaking, biotech is a pretty innovative industry — with a few notable bad apples.

With its stock surging, the creative content platform operator needs to post strong second-quarter earnings to keep its stock moving upward.

Both companies could be providing long-term investors with some great value.

Gaming, advertising technology, and emerging markets could be providing investors with some great value.

Jack’s Bitcoin addiction might be Square’s downfall.

When the going gets tough these tough investments get going.

The global market index got a big boost from its ESG business.

The company didn’t get the response it wanted from shareholders for selling additional shares.